We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DORM:NASDAQDorman Products, Inc. Analysis

Data as of 2026-06-13 - not real-time

$127.86

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Dorman Products is trading above its short‑term moving averages while sitting just below its long‑term average, indicating that momentum remains intact. The RSI is comfortably in the upper‑mid range and the MACD line sits above its signal with a positive histogram, reinforcing a bullish technical backdrop. Volume is on the rise, support sits well below the current price and the next resistance level is within reach, while the beta below one points to slightly lower market volatility.
Fundamentally, the company delivers solid revenue growth and healthy margins, with a forward earnings multiple that is markedly lower than the trailing multiple, suggesting earnings are expected to accelerate. Analysts collectively rate the stock as a strong buy with a median price target that implies a healthy upside, and the market sentiment index is in the extreme greed zone. However, the balance sheet carries a sizable debt load relative to equity and the recent earnings call highlighted a dip in operating margin due to tariff pressures, which adds a layer of near‑term caution.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and RSI indicating strong near‑term momentum
  • Price positioned above short‑term SMAs with increasing volume
  • Support level comfortably below current price providing downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward earnings multiple suggests accelerating profitability
  • Analyst consensus strong‑buy and median target price offering clear upside
  • Solid revenue growth and margin profile despite recent dip

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Cyclical nature of the auto‑aftermarket sector
  • Elevated debt‑to‑equity ratio adds balance‑sheet risk
  • Sustainable cash flow generation supports long‑term stability

Key Metrics & Analysis

Financial Health

Revenue Growth4.20%
Profit Margin8.84%
P/E Ratio20.6
ROE13.57%
ROA8.56%
Debt/Equity37.38
P/B Ratio2.6
Op. Cash Flow$106.2M
Free Cash Flow$6.2M

Technical Analysis

TrendNeutral
RSI62.2
Support$111.13
Resistance$132.15
MA 20$122.92
MA 50$116.35
MA 200$128.23
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Target Price$152.25
Upside/Downside19.08%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.91
Volatility36.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.